Global Drug Discovery Services Market is expected to reach USD 18.15 Billion by 2026 from USD XX
Billion in 2019 at CAGR of XX%.
The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders,
followers, and disrupters. Since lock down was implemented differently in different regions and
countries, impact of same is also different by regions and segments. The report has covered the current
short term and long term impact on the market, same will help decision makers to prepare the outline
for short term and long term strategies for companies by region.
To know about the Research Methodology :- Request Free Sample Report
Increasing research & development expenditure, increasing patient pool, unmet medical needs, patent
expiration of blockbuster drugs, enhancing regulatory framework, government assistance, rising funding
& reimbursement, increasing demand for outsourcing of analytical testing and clinical trial services,
inclination of major pharmaceutical companies towards outsourcing to avoid hurdles, growing
awareness about chronic diseases, is driving the drug discovery services market.
Process segment of drug discovery services is segmented into target selection, target validation, and hit-
to-lead identification. Hit-To-Lead identification is anticipated to lead maximum share. Research based
on the high-throughput screening (HTS) is the main factor driving the use of hit-to-lead identification
Medicinal chemistry, biology services, and drug metabolism and pharmacokinetics. Medicinal chemistry
segment is expected to dominate the market during the forecast period, owing to increasing number of
drug discovery and developmental activities, and increasing inclination of pharmaceutical companies
Drug type segment is bifurcated as small molecules and biologics. Small molecules are more preferred
than biologics. Small molecules are easy to characterize, simple and well defined. Small molecules can
easily enter cells, and can c